GHRP-6 vs GHRP-2

Side-by-side comparison of GHRP-6, GHRP-2 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute GHRP-6 Growth Hormone Releasing Peptide-6 Growth Hormone GHRP-2 Growth Hormone Releasing Peptide-2 Growth Hormone
Basics
Molecular type Growth Hormone Releasing Peptide (GHRP)Growth Hormone Releasing Peptide (GHRP)
Amino acids 66
Molecular weight 873.0 Da817.9 Da
Half-life ~15–60 min~1–2 hours
Route(s) Subcutaneous, Intramuscular, IntranasalSubcutaneous, Intramuscular, Intranasal
Mechanism & Research
Primary mechanism GHRP-6 activates ghrelin receptors (GHSR-1a) in both the hypothalamus and pituitary. Hypothalamic activation reduces somatostatin release (enabling larger GH pulses) and strongly activates appetite pathways — explaining … GHRP-2 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Hypothalamic activation leads to reduced somatostatin tone (the GH release inhibitor), while pituitary activation directly triggers GH se…
Research status Research Compound Research Compound
Evidence summary GHRP-6 was one of the earliest compounds to enter GHRP clinical research, with human trials dating to the early 1990s. It has been used as a reference compound for characterising GHRP biology and ghrelin receptor pharmac… GHRP-2 has been extensively studied in humans including as a diagnostic tool for GH deficiency assessment. Its well-characterised dose-response relationship makes it a reference compound in the GHRP class.
Protocol & Dosing
Typical dose 100–300 mcg per injection100–200 mcg per injection
Frequency 2–3× daily2–3x daily
Duration 8–12 weeks8–12 weeks
Timing Fasted state or 2+ hours post-mealFasted state; 2+ hours post-meal
Safety
Common side effects
  • Significant appetite increase (most common)
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Water retention
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Increased appetite
  • Water retention
Contraindications
  • Active malignancy
  • Eating disorders (appetite amplification concern)
  • Hypothyroidism
  • Active malignancy
  • Hypothyroidism
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, GHRP-2, Hexarelin, CJC-1295 Ipamorelin, CJC-1295, GHRP-6, Hexarelin
Full profile Read full GHRP-6 profile → Read full GHRP-2 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.